INTS
TOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB
08/06/2026
Back to search
Official data from USPTO
PRIAVOID
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Quick snapshot
PRIAVOID
ST13
US500000079226526Class
1, 5, 42
Filing
79226526
Registration
5582971
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
08/06/2026
Classification
Registered
Trademark type
Word
Nice classes
1, 5, 42
Filing date
06/20/2017
Registration date
10/16/2018
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
05/02/2025
Last transaction
08/06/2026
Responsible office
United States Patent and Trademark Office
Status code
709
Official register
Principal Register
Drawing code
4
Owner type
98
Owner location
DE
Examiner
RIEPEL, CHRISTINA MAXINE
Law office
N60
Current location
PUBLICATION AND ISSUE SECTION
Holders and representatives
Holders
Priavoid GmbH
P. W. (pessoa física)
Representatives
Angel Herrera, Jr. Abel Law Group, LLP
Technical classification
Nice Classes
Class 1Class 5Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 1
Chemical substances for the production of pharmaceuticals; esters of fatty acids for use in pharmaceuticals; preservatives for pharmaceutical compounds; antimicrobial preservatives for pharmaceutical compounds; chemicals for the preparation being manufacturing and production of pharmaceuticals; antioxidants for the production of pharmaceutical products; chemical compounds for the preparation being manufacturing of pharmaceutical products; esters being viscose chemicals for the production of pharmaceutical products; preservatives for use in the pharmaceutical industry; softening agents being chemical agents for manufacturing for use during the preparation of pharmaceuticals; chemical products for use in the pharmaceutical industryfor use in pharmaceutical manufacturing; active chemical ingredients for the use during the preparation being manufacturing of pharmaceuticals; biochemical compounds for scientific purposes; biochemical productsnamely polypeptides for in vitro research applications; biochemical productschemical reagents for in vitro genetic technology; reagents for use in scientific apparatus for chemical and biological analysis; diagnostic reagents for in vitro use in biochemistryclinical chemistry and microbiology; biochemicalsmonoclonal antibodies for in vitro scientific or research use
Class 5
Pharmaceuticals for the prevention and treatment of allergies and for the abatement of burns; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; pharmaceuticalsanti-infectivesimmunostimulants; implantable pharmaceuticals namelybiological tissues grafts; serotherapeutic pharmaceuticals for treatment of meningitis and respiratory disorders; pharmaceutical drugs for treatment of Alzheimer's and dementia; medicated throat sprays; medicine for dental purpose; medicine for veterinary purposebacteriostats; medicine for intestinal diseases; pharmaceutical preparations for human purposesfor treatment of Alzheimer's and dementia; pharmaceuticals for the treatment of the autonomic nervous system; pharmaceuticals for the treatment of gastrointestinal diseases; pharmaceutical compounds and products for treatment of Alzheimer's and dementia; chemical and pharmaceutical products and preparations for medical purposesmedical diagnostic reagents; antiepileptic pharmaceutical preparations; pharmaceutical compounds and substances for treatment of Alzheimer's and dementia; chemical compounds for pharmaceutical purposefor the diagnosis of pregnancy; pharmaceutical agents for metabolism; pharmaceutical agents for treatment of the intestines; pharmaceutical compounds for human usemenstrual symptom treatment preparations; synthetic peptides for pharmaceutical purpose for the prevention and treatment of flu; pharmaceutical agents and compounds for the peripheral nervous system; pharmaceutical products for the treatment of infections; pharmaceutical products for the treatment of hyperlipidemias; crystals for therapeutical purpose being pharmaceutical productsmineral preparations; pharmaceutical compounds for the prevention and treatment of metabolic disorder; pharmaceutical compounds for the treatment of kidney diseases; pharmaceutical compounds for the prevention and treatment of metabolic diseases; chemicals for pharmaceutical usechemical preparations for the diagnosis of pregnancy; pharmaceutical compounds for the treatment of a chemical imbalance; pharmaceutical preparations for the central nervous system; pharmaceutical compounds for the treatment of diabetes; pharmaceutical compounds for the treatment of Parkinson disease; pharmaceutical compounds for the treatment of multiple sclerosis; pharmaceutical compounds and substances for the prevention of cancer; pharmaceutical compounds and substances with analgesic properties; pharmaceutical compounds for the treatment of epilepsydisorders of the intestines and of the sensory organs; pharmaceutical compounds for the prevention of disorders and diseases of the nervous system; pharmaceutical compounds and substances for the treatment of cancer and cardiovascular diseases; pharmaceutical compounds and substances for use in oncology; pharmaceutical products and substances for the treatment of gastrointestinal diseases; pharmaceutical compounds for the treatment of diseases of the central nervous system (CNS); biological preparations for treatment of neurological disorders; biological compounds for the treatment of cancer; biochemical compounds for the treatment of cancer and for pain treatment; biotechnological compounds for medical purposebioactive pharmaceuticals for treatment of Alzheimer's and dementia; diagnostic biomarker reagents for medical purpose; bio-pharmaceuticals for the treatment of cancer
Class 42
Development of pharmaceutical compounds and drugs; research and development of vaccine and drugs; pharmaceutical product development in relation to drugs; pharmaceutical researchresearch regarding pharmaceuticals; conducting of quality control tests on pharmaceutical products; medical and pharmaceutical research services; pharmaceutical research and development services; pharmaceutical research and development; development of pharmaceutical products; evaluation of results from quality control tests conducted on goods and services in relation to pharmaceutical products; consulting with regard to pharmacology; laboratory research services with regard to pharmaceuticals; research in the field of pharmaceuticals; consulting with regard to pharmaceutical research and development; scientific research in the field of pharmacy; pharmaceutical product evaluationnamely services for the evaluation of the therapeutic effects of pharmaceuticals; research and development services for the pharmaceutical industry; research and development in the field of pharmacy and biotechnology; information technology (IT) consultancy services for pharmaceutical industry and health sector; quality assessment in the nature of quality testinganalysis and evaluation with regard to research in the field of pharmacogenetics; biochemical research; biological research; biological analysis; biological research services; biological development services; biological laboratory services; biochemical analysis; biomedical research; biotechnological research; research regarding biotechnologies; biotechnological research services; scientific research regarding biology; biological research and analysis; research in the field of biotechnology; consulting in the field of biology; consulting in the field of biochemistry; research and development in the field of biochemistry; research and development services in the field of biotechnology
Publications
History of USPTO decisions and trademark events.
34 publications found
INPC
INVALIDATION PROCESSED
08/06/2026
INTR
TOTAL INVALIDATION OF REG EXT PROTECTION CREATED
01/02/2026
C71T
CANCELLED SECTION 71
05/02/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
05/11/2024
REM3
COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED
10/16/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
11/19/2022
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
02/22/2019
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/31/2019
FIMP
FINAL DISPOSITION PROCESSED
01/31/2019
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/16/2019
R.PR
REGISTERED-PRINCIPAL REGISTER
10/16/2018
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/31/2018
PUBO
PUBLISHED FOR OPPOSITION
07/31/2018
GPNX
NOTIFICATION PROCESSED BY IB
07/27/2018
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
07/11/2018
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/11/2018
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
07/11/2018
CHLD
CHANGE OF OWNER RECEIVED FROM IB
07/05/2018
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/21/2018
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/21/2018
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/20/2018
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/20/2018
RFNP
REFUSAL PROCESSED BY IB
03/24/2018
CNRT
NON-FINAL ACTION MAILED
03/06/2018
CNRT
NON-FINAL ACTION WRITTEN
03/05/2018
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
03/03/2018
RFRR
REFUSAL PROCESSED BY MPU
03/02/2018
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
02/22/2018
CNRT
NON-FINAL ACTION WRITTEN
02/21/2018
MAFR
APPLICATION FILING RECEIPT MAILED
02/16/2018
DOCK
ASSIGNED TO EXAMINER
02/12/2018
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
02/12/2018
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
02/08/2018
Continuous trademark protection
Get notified about every new filing that threatens PRIAVOID or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.